Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q4 EPS of $0.68, $0.37 better than the analyst estimate of $0.31. Revenue for the quarter came in at $152.6 million versus the consensus estimate of $141.49 million.

GUIDANCE:

Catalyst Pharmaceuticals sees FY2026 revenue of $615-645 million, versus the consensus of $615.6 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.